Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

H Tian, J Cao, B Li, EC Nice, H Mao, Y Zhang… - Bone Research, 2023 - nature.com
Osteosarcoma, with poor survival after metastasis, is considered the most common primary
bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival …

Insights on functionalized carbon nanotubes for cancer theranostics

L Tang, Q Xiao, Y Mei, S He, Z Zhang, R Wang… - Journal of …, 2021 - Springer
Despite the exciting breakthroughs in medical technology, cancer still accounts for one of
the principle triggers of death and conventional therapeutic modalities often fail to attain an …

Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics

P Shi, Z Cheng, K Zhao, Y Chen, A Zhang… - Journal of …, 2023 - Springer
Osteosarcoma, the most common malignant tumor of the bone, seriously influences people's
lives and increases their economic burden. Conventional chemotherapy drugs achieve …

Carbon‐based nanomaterials for cancer therapy via targeting tumor microenvironment

J Saleem, L Wang, C Chen - Advanced healthcare materials, 2018 - Wiley Online Library
Cancer remains one of the major health problems all over the world and conventional
therapeutic approaches have failed to attain an effective cure. Tumor microenvironments …

Review on carbon nanotubes (CNTs) and their chemical and physical characteristics, with particular emphasis on potential applications in biomedicine

H Ijaz, A Mahmood, MM Abdel-Daim, RM Sarfraz… - Inorganic Chemistry …, 2023 - Elsevier
This comprehensive review article discusses the biomedical applications of carbon
nanotubes (CNTs) with unique inherent chemical and physical attributes. The findings of …

Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies

CM Hattinger, MP Patrizio, L Fantoni, C Casotti… - Cancers, 2021 - mdpi.com
Simple Summary Despite the adoption of aggressive, multimodal treatment schedules, the
cure rate of high-grade osteosarcoma (HGOS) has not significantly improved in the last 30 …

[HTML][HTML] Recent advances of drug delivery nanocarriers in osteosarcoma treatment

SY Wang, HZ Hu, XC Qing, ZC Zhang… - Journal of Cancer, 2020 - ncbi.nlm.nih.gov
Osteosarcoma is the most common primary malignant bone tumor mainly occurred in
children and adolescence, and chemotherapy is limited for the side effects and development …

Recent advances in nanoplatforms for the treatment of osteosarcoma

K Wu, B Yu, D Li, Y Tian, Y Liu, J Jiang - Frontiers in Oncology, 2022 - frontiersin.org
Osteosarcoma (OS) is the most common primary bone tumor in children and young people.
Traditional surgical excision combined with chemotherapy presents many limitations, such …

Design strategies and evolving role of biomaterial assisted treatment of osteosarcoma

M Quadros, M Momin, G Verma - Materials Science and Engineering: C, 2021 - Elsevier
Osteosarcoma is the most commonly diagnosed form of bone cancer. It is characterized by a
high risk of developing lung metastasis as the disease progresses. Standard treatment …

The heterogeneity of osteosarcoma: the role played by cancer stem cells

K Schiavone, D Garnier, MF Heymann… - Stem Cells Heterogeneity …, 2019 - Springer
Osteosarcoma is the most common bone sarcoma and is one of the cancer entities
characterized by the highest level of heterogeneity in humans. This heterogeneity takes …